Add to ORKGAbstract. To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington’s disease (HD), we carried out a prospective, open-label, randomized, controlled study. Twenty-one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no-treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration
Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric s...
OBJECTIVES: Alterations in dopamine neurotransmission underlie some of the clinical features of Hunt...
Background Dementia with Lewy bodies is a common form of dementia in the elderly, characterised clin...
Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of beha...
Sulpiride and risperidone treatment significantly improved the abnormal involuntary movements of two...
In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivas...
Objectives: Alterations in dopamine neurotransmission underlie some of the clinical features of Hunt...
Jennifer L Reingold, John C Morgan, Kapil D SethiMovement Disorders Program, Department of Neurology...
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD)...
Insufficient evidence exists to guide the long-term pharmacological management of Huntington's disea...
BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with Parkins...
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 p...
Background: Cholinergic deficits are prominent in patients who have dementia associated with Parkins...
Many patients with Parkinson’s disease suffer cognitive impairment or dementia. Cholinesterase inhib...
Insufficient evidence exists to guide the long-term pharmacological management of Huntington’s disea...
Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric s...
OBJECTIVES: Alterations in dopamine neurotransmission underlie some of the clinical features of Hunt...
Background Dementia with Lewy bodies is a common form of dementia in the elderly, characterised clin...
Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of beha...
Sulpiride and risperidone treatment significantly improved the abnormal involuntary movements of two...
In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivas...
Objectives: Alterations in dopamine neurotransmission underlie some of the clinical features of Hunt...
Jennifer L Reingold, John C Morgan, Kapil D SethiMovement Disorders Program, Department of Neurology...
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD)...
Insufficient evidence exists to guide the long-term pharmacological management of Huntington's disea...
BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with Parkins...
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 p...
Background: Cholinergic deficits are prominent in patients who have dementia associated with Parkins...
Many patients with Parkinson’s disease suffer cognitive impairment or dementia. Cholinesterase inhib...
Insufficient evidence exists to guide the long-term pharmacological management of Huntington’s disea...
Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric s...
OBJECTIVES: Alterations in dopamine neurotransmission underlie some of the clinical features of Hunt...
Background Dementia with Lewy bodies is a common form of dementia in the elderly, characterised clin...